One-third of COVID-19 survivors manifest neurological problems

Many reports of persistent symptoms indicative of long term sequelae, including neurological symptoms, are reported in patients who have recovered from COVID-19 (coronavirus disease 2019) illness. Sequela, a condition consequent of a previous injury or disease, presents new complications to therapy providers.

In this ongoing pandemic, doctors and researchers have found several post-COVID manifestations. Many COVID-19 patients experience neurological symptoms and syndromes. The long term impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19) infection on the brain is uncertain.

In a longitudinal study recently published on the preprint server medRxiv*, Andrea Pilotto et al. find that one-third of COVID-19 infection survivors have long-term neurological manifestations after hospitalization. The survivors displayed a wide array of neurological symptoms: fatigue, from memory and attention issues to sleep disorders, myalgias followed by depression/anxiety, visual disturbances, tremors, and anosmia, the loss of the sense of smell.

Prevalence of neurological symptoms in the whole samples and in subgroups of patients stratified by COVID-19 severity. Abbreviations: BCRSS, Brescia-COVID Respiratory Severity Scale; IADL, instrumental activities of daily living
Prevalence of neurological symptoms in the whole samples and in subgroups of patients stratified by COVID-19 severity. Abbreviations: BCRSS, Brescia-COVID Respiratory Severity Scale; IADL, instrumental activities of daily living

The study cohort included a sample of 165 COVID-19 survived patients who were reassessed according to a structured, standardized clinical protocol. These patients were examined six months after discharging a COVID-19 Unit of the ASST Spedali Civili Hospital, in Italy, between February and April 2020.

The team performed a 6-month follow-up after hospitalization and found that the patients suffered fatigue (34%), memory/attention (31%), and sleep disorders (30%) being the most frequent. Upon neurological examination, they found that patients exhibited neurological abnormalities, being-cognitive deficits, hyposmia (decreased sense of smell), and postural tremor, the most common.

It was observed that the patients who reported neurological symptoms were the ones affected by more severe respiratory SARS-CoV-2 infection parameters during hospitalization.

Patients with high disease severity reported memory complaints and visual disturbances. The team found that the neurological abnormalities were associated with older age, higher pre-morbid comorbidity index, worse BCRSS (Brescia-COVID Respiratory Severity Scale), longer hospitalization duration, and a higher number of neurological symptoms reported.

The best predictors of neurological abnormalities were identified in this study as 1). the duration of hospitalization and 2). the pre-morbid comorbidity index (i.e., illness present before the onset of COVID-19). The cognitive impairment was specifically associated with the severity of COVID-19 independently from age and pre-morbid conditions. It is conclusive that hospitalization and severity of COVID-19 have a large impact on patients with other illnesses.

“In this study, patients with neurological diseases developed during the acute phase of SARS-CoV-2 infection were not considered, thus potentially underestimating the global neurological burden due to COVID-19.”

This study supports previous evidence of long term consequences of COVID-19 involving both central and peripheral nervous systems. The SARS-CoV-2 infection manifested in COVID-19 is primarily a respiratory illness. However, closer examination reveals multiple organs and their functioning being impaired due to the SARS-CoV-2 infection.

Multiple neurological abnormalities, including mild cognitive impairment, have been associated with the severity of respiratory SARS-CoV-2 infection. This study evaluates any neurological manifestations after six months of follow-up in COVID-19 survivors and their potential relationship with pre-morbid conditions and severity of SARS-CoV-2 infection. The team also argues that long-term neurological problems may seem common even in patients with less severe disease. This study emphasizes the importance of evaluating the impact of SARS-CoV-2 infection on brain health status.

The “post-COVID-19 syndrome” has debilitated many lives, often forcing the survivors to return to the doctor. It is important to study and investigate the prevalence, type, duration, and severity of persistent symptoms, following the resolution of acute SARS-CoV-2 infection. This research helps to pinpoint the underlying cause  ̶  subsequently provide better rehabilitation and care for the patients.

*Important Notice

medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Journal reference:
Dr. Ramya Dwivedi

Written by

Dr. Ramya Dwivedi

Ramya has a Ph.D. in Biotechnology from the National Chemical Laboratories (CSIR-NCL), in Pune. Her work consisted of functionalizing nanoparticles with different molecules of biological interest, studying the reaction system and establishing useful applications.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Dwivedi, Ramya. (2021, January 05). One-third of COVID-19 survivors manifest neurological problems. News-Medical. Retrieved on October 03, 2022 from

  • MLA

    Dwivedi, Ramya. "One-third of COVID-19 survivors manifest neurological problems". News-Medical. 03 October 2022. <>.

  • Chicago

    Dwivedi, Ramya. "One-third of COVID-19 survivors manifest neurological problems". News-Medical. (accessed October 03, 2022).

  • Harvard

    Dwivedi, Ramya. 2021. One-third of COVID-19 survivors manifest neurological problems. News-Medical, viewed 03 October 2022,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
First data on Pfizer-BioNTech's Omicron BA.4/5 combination vaccine